Effect of chronic treatment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain

Neuroscience Research

Volumn 59, Issue 3, 2007, Pages 314-321

  Huang, Xu Feng ^a,b   Tan, Yean Yeow ^a,b   Huang, Xin ^b   Wang, Qing ^b  

^a Neuroscience Institute of Schizophrenia and Allied Disorders   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Antipsychotics; Clozapine; Gene expression; Haloperidol; Schizophrenia; Serotonin receptors

Indexed keywords

CLOZAPINE; HALOPERIDOL; MESSENGER RNA; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HISTOLOGY; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REBOUND; SCHIZOPHRENIA; SEPTUM NUCLEUS; SPRAGUE DAWLEY RAT; STATISTICAL ANALYSIS; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CLOZAPINE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; NEURAL PATHWAYS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RNA, MESSENGER; SEROTONIN; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 34948868855     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.08.001     Document Type: Article

References (40)

1. Adamec R., Creamer K., Bartoszyk G.D., and Burton P. Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats. Eur. J. Pharmacol. 504 (2004) 79-96
2. Alex K.D., Yavanian G.J., McFarlane H.G., Pluto C.P., and Pehek E.A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55 (2005) 242-251
3. Ashby Jr. C.R., and Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24 (1996) 349-394
4. Audinot V., Newman-Tancredi A., Cussac D., and Millan M.J. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. Neuropsychopharmacology 25 (2001) 410-422
5. Birzniece V., Johansson I.M., Wang M.D., Backstrom T., and Olsson T. Ovarian hormone effects on 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor mRNA expression in the ventral hippocampus and frontal cortex of female rats. Neurosci. Lett. 319 (2002) 157-161
6. Brunello N., Masotto C., Steardo L., Markstein R., and Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13 (1995) 177-213
7. Buckland P.R., D'Souza U., Maher N.A., and McGuffin P. The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT2A and 5HT2C receptors. Brain Res. Mol. Brain Res. 48 (1997) 45-52
8. Burnet P.W., Chen C.P., McGowan S., Franklin M., and Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73 (1996) 531-540
9. Burnet P.W.J., Eastwood S.L., Lacey K., and Harrison P.J. The distribution of 5-HTIA and 5-HT2A receptor mRNA in human brain. Brain Res. 676 (1995) 157-168
10. Cohen H. Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein. Depress. Anxiety 22 (2005) 84-93
11. De Deurwaerdere P., and Spampinato U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73 (1999) 1033-1042
12. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 (1990) 281-285
13. Di Giovanni G., Di Matteo V., La Grutta V., and Esposito E. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience 103 (2001) 111-116
14. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 865 (2000) 85-90
15. Gunes A., Scordo M.G., Jaanson P., and ML D. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190 (2007) 479-484
16. Hackler E.A., Turner G.H., Gresch P.J., Sengupta S., Deutch A.Y., Avison M.J., Gore J.C., and Sanders-Bush E. 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J. Pharmacol. Exp. Ther. 320 (2007) 1023-1029
17. Heisler L.K., Zhou L., Bajwa P., Hsu J., and Tecott L.H. Serotonin 5-HT2C receptors regulate anxiety-like behavior. Gen. Brain Behav. 6 (2007) 491-496
18. Huang X.F., Deng C., and Zavitsanou K. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 40 (2006) 213-219
19. Huang X.F., Han M., and Storlien L.H. Differential expression of 5-HT(2A) and 5-HT(2C) receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res. Mol. Brain Res. 127 (2004) 39-47
20. Ikeguchi K., and Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci. 244 (1995) 320-324
21. Kusljic S., Brosda J., and van den Buuse M. Effects of haloperidol and clozapine on sensorimotor gating deficits induced by 5-hydroxytryptamine depletion in the brain. Br. J. Pharmacol. 147 (2006) 800-807
22. Kusumi I., Matsubara S., Takahashi Y., Ishikane T., and Koyama T. Characterization of [3H]clozapine binding sites in rat brain. J. Neural. Transm. Gen. Sect. 101 (1995) 51-64
23. Lane R.F., Blaha C.D., and Rivet J.M. Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: Involvement of a,-noradrenergic receptors demonstrated by in vivo voltametry. Brain Res. 460 (1988) 398-401
24. Liegeois J.F., Ichikawa J., and Meltzer H.Y. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947 (2002) 157-165
25. Marazziti D., Rossi A., Giannaccini G., Zavaglia K.M., Dell'Osso L., Lucacchini A., and Cassano G.B. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur. Neuropsychopharmacol. 10 (1999) 21-26
26. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., Cola P., Howard A., Badri F., Nothen M.M., Kalow W., and Kennedy J.L. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19 (1998) 123-132
27. Meltzer H.Y. Arvanitis L. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161 (2004) 975-984
28. Nic Dhonnchadha B.A., Ripoll N., Clenet F., Hascoet M., and Bourin M. Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology 179 (2005) 418-429
29. Ojima T., Ito C., Sakurai E., Sakurai E., Watanabe T., and Yanai K. Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex. Neurosci. Lett. 366 (2004) 130-134
30. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
31. Pozzi L., Acconcia S., Ceglia I., Invernizzi R.W., and Samanin R. Stimulation of 5-hydroxytryptamine (5-HT(2C)) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J. Neurochem. 82 (2002) 93-100
32. Remington G., and Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology (Berl.) 148 (2000) 3-15
33. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
34. Steward L.J., Kennedy M.D., Morris B.J., and Pratt J.A. The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors. Neuropharmacology 47 (2004) 527-537
35. Timmerman W., Heijmen M., Westerink B.H., Bruggeman R., and den Boer J.A. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacology (Berl.) 144 (1999) 286-294
36. Trevitt J.T., Lyons M., Aberman J., Carriero D., Finn M., and Salamone J.D. Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology (Berl.) 132 (1997) 74-81
37. Van Oekelen D., Luyten W.H., and Leysen J.E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 72 (2003) 2429-2449
38. Weisstaub N.V., Zhou M., Lira A., Lambe E., Gonzalez-Maeso J., Hornung J.P., Sibille E., Underwood M., Itohara S., Dauer W.T., Ansorge M.S., Morelli E., Mann J.J., Toth M., Aghajanian G., Sealfon S.C., Hen R., and Gingrich J.A. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313 (2006) 536-540
39. Wolf W.A., Bieganski G.J., Guillen V., and Mignon L. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl.) 182 (2005) 84-94
40. Zavitsanou K., Nguyen V.H., Han M., and Huang X.F. Effects of Typical and Atypical Antipsychotic Drugs on Rat Brain Muscarinic Receptors. Neurochem. Res. 32 (2007) 525-532